MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414169 | Name: Exaprolol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Exaprolol HCl is an Anti-Adrenergic (beta-Receptor)

Chemical Structure

Exaprolol HCl
Exaprolol HCl
CAS#59333-90-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 414169

Name: Exaprolol HCl

CAS#: 59333-90-3 (HCl)

Chemical Formula: C18H30ClNO2

Exact Mass:

Molecular Weight: 327.89

Elemental Analysis: C, 65.94; H, 9.22; Cl, 10.81; N, 4.27; O, 9.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
59333-90-3 (HCl) 55837-19-9 (free base)
Synonym
Exaprolol HCl; Exaprolol hydrochloride; M.G.8823; M.G.-8823; M.G. 8823
IUPAC/Chemical Name
2-Propanol, 1-(2-cyclohexylphenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)-
InChi Key
ODWXZMXQBDEIBF-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H29NO2.ClH/c1-14(2)19-12-16(20)13-21-18-11-7-6-10-17(18)15-8-4-3-5-9-15;/h6-7,10-11,14-16,19-20H,3-5,8-9,12-13H2,1-2H3;1H
SMILES Code
OC(CNC(C)C)COC1=CC=CC=C1C2CCCCC2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 327.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: van Waarde A, Doorduin J, de Jong JR, Dierckx RA, Elsinga PH. Synthesis and preliminary evaluation of (S)-[11C]-exaprolol, a novel beta-adrenoceptor ligand for PET. Neurochem Int. 2008 Mar-Apr;52(4-5):729-33. Epub 2007 Sep 19. PubMed PMID: 17961850. 2: Tomcíková O, Bezek S, Durisová M, Faberová V, Zemánek M, Trnovec T. Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. Biopharm Drug Dispos. 1984 Apr-Jun;5(2):153-62. PubMed PMID: 6146357. 3: Mojzis J, Nicák A, Linková A, Jandoseková M, Mirossay L. Differences between cation-osmotic hemolysis and filterability in exaprolol- and glutaraldehyde-treated human red blood cells. Physiol Res. 1999;48(6):411-6. PubMed PMID: 10783905. 4: Dzurba A, Barta E, Styk J, Okolicány J, Ziegelhöffer A. The influence of exaprolol upon the ischaemic rat heart and its interaction with sarcolemmal (Na+ + K+)-ATPase. Physiol Bohemoslov. 1989;38(1):29-39. PubMed PMID: 2566182. 5: Trnovec T, Zemánek M, Faberová V, Bezek S, Durisová M, Ujházy E, Tomcíková O. Disposition of exaprolol, a new beta-blocker, in rats. Drug Metab Dispos. 1982 Sep-Oct;10(5):547-50. PubMed PMID: 6128208. 6: Motheová O, Zemánek M, Faberova V, Trnovec T, Gabauer I, Styk J, Durisová M, Nosálová V. Absorption of exaprolol from the in-situ gastrointestinal tract of rats and dogs. J Pharm Pharmacol. 1985 Nov;37(11):816-9. PubMed PMID: 2867165. 7: Parratt JR, Udvary E. The effect of exaprolol (MG 8823) on epicardial ST-segment changes in a feline model of acute myocardial ischaemia. Br J Pharmacol. 1983 Sep;80(1):95-105. PubMed PMID: 6652377; PubMed Central PMCID: PMC2044960. 8: Hughes B, Kane KA, McDonald FM, Parratt JR. Aspects of the cardiovascular pharmacology of exaprolol. J Pharm Pharmacol. 1984 Sep;36(9):597-601. PubMed PMID: 6149283. 9: Dzurba A, Ziegelhöffer A, Schmidtová L, Breier A, Vrbjar N, Okolicány J. Exaprolol as a modulator of heart sarcolemmal (Na+ + K+)-ATPase. Evidence for interaction with an essential sulfhydryl group in the catalytic centre of the enzyme. Gen Physiol Biophys. 1985 Jun;4(3):257-64. PubMed PMID: 2863195. 10: Faberová V, Trnovec T, Zemánek M, Bezek S, Durisová M, Tomcíková O. Tissue distribution of exaprolol in rat. Eur J Drug Metab Pharmacokinet. 1985 Jan-Mar;10(1):11-3. PubMed PMID: 2863149. 11: Linková A, Nicák A. [The effect of exaprolol and sodium salicylate on erythrocyte hemolysis in relation to age]. Bratisl Lek Listy. 1990 Jan;91(1):52-6. Slovak. PubMed PMID: 1969763. 12: Pecivová J, Drábiková K, Jancinová V, Petríková M, Nosál R. Atenolol, exaprolol and mast cell membranes. Agents Actions. 1991 May;33(1-2):41-3. PubMed PMID: 1680276. 13: Bilcíková L, Bauer V, Kolena J. The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. PubMed PMID: 2885244. 14: Nicák A, Linková A, Kohút A. [Hemolytic effect of exaprolol and its dependence on the age of rats]. Bratisl Lek Listy. 1982 Nov;78(5):554-9. Slovak. PubMed PMID: 6129052. 15: Babul'ová A, Buran L. [Analysis of the effect of exaprolol on bronchospasm in guinea pigs (author's transl)]. Bratisl Lek Listy. 1981 Oct;76(4):471-80. Slovak. PubMed PMID: 6117354. 16: Nosál' R, Drábiková K, Pecivová J, Ondrias K, Jakubovský J. [Analysis of the adverse effects of drugs at the cellular and subcellular levels]. Cesk Farm. 1990 May;39(3):118-21. Slovak. PubMed PMID: 1698127. 17: Pecivová J, Drábiková K, Nosál R. Effect of beta-adrenoceptor blocking drugs on 32P incorporation into and arachidonic acid liberation from phospholipids in stimulated rat mast cells. Agents Actions. 1989 Apr;27(1-2):29-32. PubMed PMID: 2568743. 18: Ujházy E, Balonová T, Rippa S, Buran L, Babul'ová A. [Evaluation of the effects of exaprolol (VULM 111) on the prenatal development in mice and rats (author's transl)]. Bratisl Lek Listy. 1981 Dec;76(6):664-73. Slovak. PubMed PMID: 6119142. 19: Motheová O, Bezek S, Durisová M, Faberová V, Zemánek M, Misánikova K, Trnovec T. The pharmacokinetics of exaprolol and propranolol in rats with interrupted enterohepatic circulation. Biopharm Drug Dispos. 1986 Mar-Apr;7(2):151-62. PubMed PMID: 2871875. 20: Carissimi M, Gentili P, Grumelli E, Milla E, Picciola G, Ravenna F. Basic ethers of cyclohexylphenols with beta-blocking activity: synthesis and pharmacological study of exaprolol. Arzneimittelforschung. 1976 Apr;26(4):506-16. PubMed PMID: 8056.

View History

Evogliptin HCl

Evogliptin HCl

UR-PG131A

UR-PG131A

YS 51

YS 51

Uredofos

Uredofos

YUN23223

YUN23223

OXI-4503 dipotassium salt

OXI-4503 dipotassium salt